腫瘍学における人工知能市場：製品タイプ、技術、がんタイプ、用途、最終用途別-2025-2030年の世界予測

腫瘍学における人工知能市場は、2024年には232億5,000万米ドルとなり、2025年には276億7,000万米ドル、CAGR20.23%で成長し、2030年には702億6,000万米ドルに達すると予測されています。

人工知能は、臨床ワークフローと患者ケアを再定義するブレークスルーを促進し、腫瘍学の展望を再構築する極めて重要な力として台頭してきました。テクノロジーが医療と融合する時代において、高度なアルゴリズムとデータ分析の統合は、ヘルスケア環境におけるより正確な診断、個別化された治療計画、業務効率の改善への道を開きます。本レポートでは、高度なAIソリューションが診断精度を高めるだけでなく、創薬の促進や治療計画の最適化においても重要な役割を果たしていることを検証します。

腫瘍学におけるAIの進化は、意思決定と患者の転帰予測の可能性を高める重要な技術的進歩によって特徴付けられます。画像解析から予測モデリングに至るまで、こうした動向は、よりダイナミックで応答性の高いがん医療を目指す傾向を浮き彫りにしています。さらに、臨床医と技術者の能力を組み合わせた学際的チームがAIを活用して複雑なデータパターンを解釈し、実用的な洞察を提供することで、ヘルスケアの状況はパラダイムシフトを目の当たりにしています。医療の専門知識と最先端技術の融合は、新たな課題に対処し、この分野における新たな機会を引き出すための強固な基盤を築きました。

AIが牽引するオンコロジー領域における変革的シフト

人工知能は単なる漸進的な革新ではなく、腫瘍学の分野における根本的な変革を意味します。一連の画期的なシフトは、ヘルスケアプロバイダーががん診断、治療計画、患者管理にどのようにアプローチするかを再定義しています。機械学習、高度な画像処理、予測分析の統合は、従来の方法がより高い精度と効率性を目指して再構築される新時代の到来を告げています。

自動画像診断やリアルタイムの手術支援といった革新的なアプリケーションは、理論的な可能性を日常的な臨床の現実に変えています。この変革の旅は、アルゴリズム、データ管理技術、センサーシステムの絶え間ない改善によって支えられており、これらの技術によってAI駆動型アプリケーションの信頼性と拡張性が強化されています。さらに、クラウドベースやオンプレミスのソリューションに向かう動向は、ヘルスケアプロバイダーに柔軟性を提供し、進化する規制要件や患者の期待にシームレスに適応することを可能にします。

こうしたシフトの影響は、診断ミスの減少、意思決定プロセスの迅速化、患者体験全体の顕著な改善において明らかです。AIを既存のヘルスケア・インフラとシームレスに統合することで、業界の利害関係者は、患者ケアに革命をもたらし、がん領域全体の業務基準を再定義することを約束する新たなベンチマークを設定しつつあります。

主要セグメントに関する洞察市場力学の詳細調査

市場を詳細に分析すると、複雑で階層化されたセグメンテーション構造が、がん領域のイノベーションを促進し、成長を促していることがわかる。セグメンテーションの1層は製品タイプに基づくもので、市場はハードウェア、サービス、ソフトウェア・ソリューションに分類されます。ハードウェアでは、画像診断システムとロボット手術システムに重点が置かれ、サービスではコンサルティングと導入サービスの両方に重点が置かれています。ソフトウェアソリューションのセグメントは、クラウドベースのソリューションとオンプレミスのツールにさらに細分化され、それぞれがヘルスケアプロバイダーに独自の利点を提供しています。

技術に基づくセグメンテーションは、コンピュータ・ビジョン、機械学習、自然言語処理、ロボティック・プロセス・オートメーションなどのセグメントを分析することで、この視点をさらに豊かにします。コンピュータ・ビジョンは、正確な画像診断に不可欠な3D再構成、画像認識、ビデオ解析に関連して複雑に調査しています。機械学習は、深層学習、教師あり学習、教師なし学習のサブセットを通して探求され、自然言語処理は、データ注釈、感情分析、テキストマイニングをカバーし、より微妙な洞察を促進します。ロボットによるプロセス自動化の進歩は、自動ワークフロー、臨床文書化、プロセスマッピングにおけるイノベーションを支えます。

さらに、市場セグメンテーションは、乳がん、子宮頸がん、大腸がん、食道がん、肝臓がん、肺がん、皮膚がん、胃がん、甲状腺がんなどを包括的にカバーするがんタイプ別のセグメンテーションにも及んでおり、疾患別の動向を詳細に把握することができます。市場セグメンテーションではさらに、市場を診断、創薬、転帰予測、個別化医療、治療計画に分類しています。各アプリケーションカテゴリーには、診断における画像解析、分子診断、病理学、創薬における臨床試験デザイン、リード探索、ターゲット同定、同様に転帰予測、個別化医療、治療計画といったサブドメインが用意されています。最後に、最終用途のセグメンテーションでは、診断ラボ、病院、製薬会社、研究機関における用途に沿って市場を区別し、さらにゲノム検査施設、病理ラボ、さまざまな病院タイプ、メーカー分類、学術機関やバイオテクノロジー企業を含む研究機関へと掘り下げています。

この階層的なセグメンテーションは、市場力学の多様性を示すだけでなく、がん領域全体の特定のニーズに対応するテーラーメイドのAIアプリケーションの可能性を示すものでもあります。これらのセグメント化された洞察を活用することで、利害関係者は、患者ケアを強化しながらイノベーションと業務効率の両方を推進するニッチと機会を特定することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがん患者が増加しており、ケアを強化するための革新的なAIソリューションが必要となっています。
    • ヘルスケアにおけるAI調査に対する政府の取り組みと資金提供が腫瘍学におけるイノベーションと導入を促進
  • 抑制要因
    • AIの開発と導入に伴う高コストと相互運用性の問題
  • 機会
    • 腫瘍学ケアプロバイダーとAIテクノロジープロバイダー間の重要なパートナーシップ
    • 遠隔医療と遠隔モニタリングの急増により、AIを活用した遠隔腫瘍学サービスとケアが強化される
  • 課題
    • 公平な腫瘍治療を提供するために、AIアルゴリズムの公平性を確保し、バイアスを軽減することの課題
• 市場セグメンテーション分析
  • 製品タイプ：データ管理とターゲットを絞った意思決定のためのソフトウェアソリューションの大幅な開発
  • 最終用途：ジェネリック医薬品メーカーの生産効率と品質管理対策を強化するAIソリューションの進歩
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 腫瘍学における人工知能市場：製品タイプ別

• ハードウェア
  • 診断画像システム
  • ロボット手術システム
• サービス
  • コンサルティングサービス
  • 実装サービス
• ソフトウェアソリューション
  • クラウドベースのソリューション
  • オンプレミスツール

第7章 腫瘍学における人工知能市場：技術別

• コンピュータビジョン
  • 3D再構築
  • 画像認識
  • ビデオ分析
• 機械学習
  • ディープラーニング
  • 教師あり学習
  • 教師なし学習
• 自然言語処理
  • データ注釈
  • 感情分析
  • テキストマイニング
• ロボティックプロセスオートメーション
  • 自動化されたワークフロー
  • 臨床文書
  • プロセスマッピング

第8章 腫瘍学における人工知能市場がんの種類別

• 乳がん
• 子宮頸がん
• 大腸がん
• 食道がん
• 肝臓がん
• 肺がん
• 皮膚がん
• 胃がん
• 甲状腺がん

第9章 腫瘍学における人工知能市場：用途別

• 診断
  • 画像解析
  • 分子診断
  • 病理学
  • スクリーニング
• 創薬
  • 臨床試験の設計
  • リード発見
  • ターゲット識別
• 結果予測
  • 合併症予測
  • 応答予測
  • 生存率の可視化
• パーソナライズ医療
  • バイオマーカーの特定
  • ゲノムデータ分析
  • 治療の最適化
• 治療計画
  • 化学療法計画
  • 放射線治療計画
  • 手術計画

第10章 腫瘍学における人工知能市場：最終用途別

• 診断検査室
  • ゲノム検査施設
  • 病理学研究室
• 病院
  • 私立病院
  • 公立病院
• 製薬会社
  • ジェネリックメーカー
  • イノベーター企業
• 調査機関
  • 学術機関
  • バイオテクノロジー企業

第11章 南北アメリカの腫瘍学における人工知能市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の腫瘍学における人工知能市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの腫瘍学における人工知能市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amazon Web Services, Inc.
• Arterys, Inc.
• Berg LLC
• Bristol-Myers Squibb Company
• Butterfly Network, Inc.
• F. Hoffmann-La Roche Ltd.
• Flatiron Health, Inc.
• Freenome Holdings, Inc.
• GE Healthcare
• Google LLC by Alphabet Inc.
• IBM Corporation
• Intel Corporation
• Koninklijke Philips N.V.
• Medial EarlySign Ltd.
• Microsoft Corporation
• Nvidia Corporation
• Oncora Medical, Inc.
• Paige.AI Inc.
• PathAI, Inc.
• Siemens Healthineers AG
• Tempus Labs, Inc.
• Ultromics Limited
• Viz.ai, Inc.
• Zebra Medical Vision Ltd.

LIST OF FIGURES

• FIGURE 1. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET MULTI-CURRENCY
• FIGURE 2. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET MULTI-LANGUAGE
• FIGURE 3. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET RESEARCH PROCESS
• FIGURE 4. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET DYNAMICS
• TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC IMAGING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC SURGICAL SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMPLEMENTATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLOUD-BASED SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ON-PREMISE TOOLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY 3D RECONSTRUCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMAGE RECOGNITION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY VIDEO ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DATA ANNOTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SENTIMENT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TEXT MINING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY AUTOMATED WORKFLOWS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLINICAL DOCUMENTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PROCESS MAPPING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STOMACH (GASTRIC) CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLINICAL TRIALS DESIGN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPLICATION PREDICTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESPONSE PREDICTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURVIVAL RATE VISUALIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BIOMARKER IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY GENOMIC DATA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THERAPEUTIC OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY PLANNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RADIATION THERAPY PLANNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURGICAL PLANNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY GENOMIC TESTING FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PATHOLOGY LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY GENERIC MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY INNOVATOR COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
• TABLE 95. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 97. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 98. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 99. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 101. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 102. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 103. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 104. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 105. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 107. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 108. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 109. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 110. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 111. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 113. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 114. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 115. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
• TABLE 116. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 117. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 119. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 120. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 121. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 123. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 124. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 125. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 126. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 129. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 130. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 131. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 132. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 133. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 134. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 135. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 136. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 137. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
• TABLE 138. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 140. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 141. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 142. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 144. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 145. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 146. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 147. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 148. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 150. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 151. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 152. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 153. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 154. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 155. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 156. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 157. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 158. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
• TABLE 159. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 160. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 161. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 162. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 163. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 165. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 166. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 167. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 168. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 169. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 171. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 172. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 173. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 174. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 175. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 176. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 177. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 178. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 179. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
• TABLE 180. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 182. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 183. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 184. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 186. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 187. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 188. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 189. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 190. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 192. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 193. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 194. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 195. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 196. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 197. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 198. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 199. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 200. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
• TABLE 201. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 203. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 204. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 205. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 206. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 207. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 208. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 209. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 210. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 211. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 213. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 214. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 215. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 216. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 217. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 218. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 219. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 220. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 221. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
• TABLE 222. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 223. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 224. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 225. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 226. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 227. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 228. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 229. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 230. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 231. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 232. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 233. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 234. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 235. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 236. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 237. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 238. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 239. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 240. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 241. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 242. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 243. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
• TABLE 244. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 245. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 246. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 247. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 248. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 249. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 250. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 251. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 252. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 253. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 254. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 255. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 256. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 257. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 258. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 259. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 260. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 261. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 262. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 263. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 264. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 265. AUSTRALIA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
• TABLE 266. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 267. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 268. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 269. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 270. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 271. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
• TABLE 272. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
• TABLE 273. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
• TABLE 274. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
• TABLE 275. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 276. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 277. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 278. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 279. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2030 (USD MILLION)
• TABLE 280. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 281. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2030 (USD MILLION)
• TABLE 282. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 283. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 284. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 285. CHINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET

The Artificial Intelligence in Oncology Market was valued at USD 23.25 billion in 2024 and is projected to grow to USD 27.67 billion in 2025, with a CAGR of 20.23%, reaching USD 70.26 billion by 2030.

Artificial Intelligence has emerged as a pivotal force in reshaping the landscape of oncology, facilitating breakthroughs that redefine clinical workflows and patient care. In an era where technology converges with medicine, the integration of advanced algorithms and data analytics paves the way for more precise diagnostics, personalized treatment plans, and improved operational efficiencies in healthcare environments. This report examines how sophisticated AI solutions are not only augmenting diagnostic accuracy but are also playing an instrumental role in accelerating drug discovery and optimizing treatment planning.

The evolution of AI in oncology is marked by significant technological advancements that enhance decision-making and patient outcome predictability. From image analysis to predictive modeling, these developments underscore a trend toward more dynamic and responsive cancer care. Furthermore, the healthcare landscape is witnessing a paradigm shift as interdisciplinary teams, combining the prowess of clinicians and technologists, leverage AI to interpret complex data patterns and deliver actionable insights. The convergence of medical expertise with state-of-the-art technology lays a robust foundation for addressing emerging challenges and unlocking new opportunities within the sector.

Transformative Shifts in the Oncology Landscape Driven by AI

Artificial Intelligence is not just an incremental innovation; it represents a radical transformation in the field of oncology. A series of groundbreaking shifts are redefining how healthcare providers approach cancer diagnosis, treatment planning, and patient management. The integration of machine learning, advanced image processing, and predictive analytics has ushered in a new era where traditional methods are reimagined for greater precision and efficiency.

Innovative applications such as automated diagnostic imaging and real-time surgical assistance are turning theoretical possibilities into everyday clinical realities. This transformative journey is supported by continuous improvements in algorithms, data management technologies, and sensor systems, which collectively bolster the reliability and scalability of AI-driven applications. Furthermore, the trend towards cloud-based and on-premise solutions offers flexibility to healthcare providers, allowing them to adapt seamlessly to evolving regulatory requirements and patient expectations.

The impact of these shifts is evident in the reduction of diagnostic errors, faster decision-making processes, and a marked improvement in the overall patient experience. By seamlessly integrating AI with existing healthcare infrastructures, industry stakeholders are setting new benchmarks that promise to revolutionize patient care and redefine operational standards across the oncology spectrum.

Key Segmentation Insights: A Detailed Examination of Market Dynamics

An in-depth analysis of the market reveals a complex and tiered segmentation structure that is driving innovation and fueling growth in the realm of oncology. One layer of segmentation is based on product type, where the market is dissected into hardware, services, and software solutions. Within hardware, significant emphasis is placed on diagnostic imaging systems and robotic surgical systems, while the services category delves into both consulting and implementation services. The software solutions segment further subdivides into cloud-based solutions and on-premise tools, each offering unique advantages to healthcare providers.

The segmentation based on technology further enriches this perspective by analyzing segments such as computer vision, machine learning, natural language processing, and robotic process automation. Computer vision is intricately studied in relation to 3D reconstruction, image recognition, and video analysis, which are critical for precise imaging diagnostics. Machine learning is explored through its subsets of deep learning, supervised learning, and unsupervised learning, while natural language processing covers data annotation, sentiment analysis, and text mining to facilitate more nuanced insights. Advances in robotic process automation underpin innovations in automated workflows, clinical documentation, and process mapping.

Additionally, the market analysis extends to segmentation by cancer type, which comprehensively covers breast cancer, cervical cancer, colorectal cancer, esophageal cancer, liver cancer, lung cancer, skin cancer, stomach (gastric) cancer, and thyroid cancer, providing a granular view of disease-specific trends. Application segmentation further categorizes the market into diagnostics, drug discovery, outcome prediction, personalized medicine, and treatment planning. Each application category opens up subdomains such as imaging analytics, molecular diagnostics, and pathology under diagnostics; clinical trial design, lead discovery, and target identification in drug discovery; and, similarly, specialized focus areas across outcome prediction, personalized medicine, and treatment planning. Finally, the end-use segmentation distinguishes the market along the use in diagnostic laboratories, hospitals, pharmaceutical companies, and research institutions, with further drilling down into genomic testing facilities, pathology labs, varied hospital types, manufacturer classifications, and research institutions including academic and biotech entities.

This layered segmentation not only illustrates the diversity of market dynamics but also signals the potential for tailored AI applications that cater to specific needs across the oncology spectrum. By leveraging these segmented insights, stakeholders can identify niches and opportunities that drive both innovation and operational efficiency while enhancing patient care.

Based on Product Type, market is studied across Hardware, Services, and Software Solutions. The Hardware is further studied across Diagnostic Imaging Systems and Robotic Surgical Systems. The Services is further studied across Consulting Services and Implementation Services. The Software Solutions is further studied across Cloud-Based Solutions and On-Premise Tools.

Based on Technology, market is studied across Computer Vision, Machine Learning, Natural Language Processing, and Robotic Process Automation. The Computer Vision is further studied across 3D Reconstruction, Image Recognition, and Video Analysis. The Machine Learning is further studied across Deep Learning, Supervised Learning, and Unsupervised Learning. The Natural Language Processing is further studied across Data Annotation, Sentiment Analysis, and Text Mining. The Robotic Process Automation is further studied across Automated Workflows, Clinical Documentation, and Process Mapping.

Based on Cancer Type, market is studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer, Lung Cancer, Skin Cancer, Stomach (Gastric) Cancer, and Thyroid Cancer.

Based on Application, market is studied across Diagnostics, Drug Discovery, Outcome Prediction, Personalized Medicine, and Treatment Planning. The Diagnostics is further studied across Imaging Analytics, Molecular Diagnostics, Pathology, and Screening. The Drug Discovery is further studied across Clinical Trials Design, Lead Discovery, and Target Identification. The Outcome Prediction is further studied across Complication Prediction, Response Prediction, and Survival Rate Visualization. The Personalized Medicine is further studied across Biomarker Identification, Genomic Data Analysis, and Therapeutic Optimization. The Treatment Planning is further studied across Chemotherapy Planning, Radiation Therapy Planning, and Surgical Planning.

Based on End-Use, market is studied across Diagnostic Laboratories, Hospitals, Pharmaceutical Companies, and Research Institutions. The Diagnostic Laboratories is further studied across Genomic Testing Facilities and Pathology Labs. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Pharmaceutical Companies is further studied across Generic Manufacturers and Innovator Companies. The Research Institutions is further studied across Academic Institutions and Biotech Firms.

Key Regional Insights: Navigating Global Opportunities in Oncology

Regional dynamics play a critical role in shaping the adoption and expansion of AI-driven oncology solutions. The Americas continue to be at the forefront, driven by significant investments in healthcare technology and well-established research ecosystems. In this region, robust regulatory frameworks coupled with a high level of digital infrastructure support the rapid implementation of AI applications, thereby enhancing both diagnostic capabilities and treatment planning.

In contrast, the Europe, Middle East & Africa region presents a diverse mix of opportunities and challenges. European nations have long been pioneers in integrating technological advancements within their healthcare systems, benefiting from collaborative research and stringent regulatory standards. Meanwhile, emerging markets in the Middle East and Africa are rapidly embracing innovative healthcare technologies, leveraging AI to improve access to quality care and bridge the gap in service delivery.

The Asia-Pacific region is marked by dynamic growth, with substantial investments in research and development fueling advancements in oncology. The expanding digital ecosystem, combined with a large patient base and government initiatives towards healthcare modernization, makes Asia-Pacific a fertile ground for implementing advanced AI solutions. These regional insights underscore the importance of tailoring strategies to local market needs while exploiting global opportunities presented by the transformative capabilities of AI in oncology.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights: Industry Leaders Driving Innovation in Oncology

Leading companies are at the heart of the AI revolution in oncology, each contributing to the rapid evolution of technology and clinical practice. The involvement of industry giants and innovative startups is reshaping the competitive landscape. Amazon Web Services, Inc. stands out as a prominent force, offering cloud computing power that underpins many AI solutions. Arterys, Inc. and Berg LLC are making significant strides with advanced analytical tools that integrate seamlessly into clinical workflows.

Bristol-Myers Squibb Company plays a vital role in bridging the gap between pharmaceuticals and AI, while Butterfly Network, Inc. is celebrated for its breakthrough innovations in portable imaging devices. The contributions of F. Hoffmann-La Roche Ltd. and Flatiron Health, Inc. further highlight a commitment to leveraging data for enhanced diagnostic accuracy and treatment personalization. Freenome Holdings, Inc. is at the forefront of early cancer detection, using AI to analyze complex datasets for early intervention.

Major technology providers such as GE Healthcare, Google LLC by Alphabet Inc., and IBM Corporation bring exceptional expertise in data processing and machine learning. Intel Corporation and Koninklijke Philips N.V. are innovating in the hardware space with advanced imaging and diagnostic instruments. Medial EarlySign Ltd., Microsoft Corporation, Nvidia Corporation, and Oncora Medical, Inc. are collectively advancing the field through integrated solutions that combine clinical data with AI insights. Emerging leaders like Paige.AI Inc., PathAI, Inc., Siemens Healthineers AG, Tempus Labs, Inc., Ultromics Limited, Viz.ai, Inc., and Zebra Medical Vision Ltd. also contribute significantly by harnessing novel technologies that promise to transform every aspect of oncology care.

This varied collection of industry players not only underscores the global commitment to advancing cancer care but also hints at the synergies that will continue to drive innovation in AI-driven oncology solutions.

The report delves into recent significant developments in the Artificial Intelligence in Oncology Market, highlighting leading vendors and their innovative profiles. These include Amazon Web Services, Inc., Arterys, Inc., Berg LLC, Bristol-Myers Squibb Company, Butterfly Network, Inc., F. Hoffmann-La Roche Ltd., Flatiron Health, Inc., Freenome Holdings, Inc., GE Healthcare, Google LLC by Alphabet Inc., IBM Corporation, Intel Corporation, Koninklijke Philips N.V., Medial EarlySign Ltd., Microsoft Corporation, Nvidia Corporation, Oncora Medical, Inc., Paige.AI Inc., PathAI, Inc., Siemens Healthineers AG, Tempus Labs, Inc., Ultromics Limited, Viz.ai, Inc., and Zebra Medical Vision Ltd.. Actionable Recommendations for Strategic Leadership in AI-Driven Oncology

Industry leaders are encouraged to adopt a forward-thinking approach that capitalizes on the transformative potential of AI in oncology. It is crucial to align investment strategies with emerging trends in technology, segmentation, and regional market dynamics. Decision-makers should prioritize the integration of robust AI systems that enhance diagnostic accuracy and streamline treatment processes, ensuring that clinical innovations translate into tangible patient benefits.

To secure a competitive edge, organizations must focus on fostering collaborative environments where cross-disciplinary teams can innovate effectively. By investing in strong data infrastructure and scalable AI solutions, healthcare providers can better manage the complexities of modern oncology care. Additionally, tailored strategies that consider regional regulatory frameworks and local market needs are imperative. Leaders must harness insights derived from detailed segmentation analysis-ranging from product type and specific technological advancements to cancer types and end-user scenarios-to ensure that strategic initiatives are both data-driven and contextually relevant.

Moreover, partnerships with leading technology providers and academic institutions should be prioritized to facilitate research and development. This collaboration could drive the refinement of algorithms and promote the standardization of AI applications in clinical settings. Lastly, continuous monitoring of key performance indicators and regular updates to strategic plans will ensure that organizations remain agile in the face of evolving industry trends, thereby transforming challenges into growth opportunities.

Conclusion: Embracing the Future of Oncology with AI Innovation

The synthesis of advanced AI technologies with the intricacies of oncology care represents a landmark shift in the healthcare industry. As this analysis has demonstrated, the evolution of AI in oncology is characterized by transformative shifts in clinical practice, multifaceted market segmentation, dynamic regional influences, and the significant participation of key industry players. These elements together form the backbone of a future where predictive analytics, automated diagnostic systems, and personalized treatment planning are not merely aspirational goals but integral components of everyday clinical practice.

Central to this paradigm shift is the recognition that the convergence of technology, data science, and clinical expertise heralds significant improvements in patient outcomes, operational efficiencies, and overall healthcare delivery. By moving beyond traditional methodologies and embracing innovative AI-driven solutions, the industry is set to redefine standards of care in a rapidly evolving medical landscape.

This comprehensive overview reaffirms the importance of adopting an integrated approach that not only recognizes the current industry capabilities but also anticipates future challenges and opportunities. The continued collaboration between technology innovators and healthcare providers will be critical in steering the oncology sector toward a new era of precision, efficiency, and patient-centric care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer cases globally necessitates innovative AI solutions to enhance care
    • 5.1.1.2. Government initiatives and funding for AI research in healthcare drive innovation and adoption in oncology
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with AI development and deployment along with interoperability issues
  • 5.1.3. Opportunities
    • 5.1.3.1. Significant partnerships between oncology care provider and AI technology providers
    • 5.1.3.2. Surge in telemedicine and remote monitoring bolsters AI-enabled remote oncology services and care
  • 5.1.4. Challenges
    • 5.1.4.1. Challenges in ensuring fairness and mitigating biases in AI algorithms to provide equitable oncology care
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Significant development of the software solutions for data management and targeted decision-making
  • 5.2.2. End-Use: Advancements in AI solutions to enhance production efficiencies and quality control measures for generic manufacturers
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Artificial Intelligence in Oncology Market, by Product Type

• 6.1. Introduction
• 6.2. Hardware
  • 6.2.1. Diagnostic Imaging Systems
  • 6.2.2. Robotic Surgical Systems
• 6.3. Services
  • 6.3.1. Consulting Services
  • 6.3.2. Implementation Services
• 6.4. Software Solutions
  • 6.4.1. Cloud-Based Solutions
  • 6.4.2. On-Premise Tools

7. Artificial Intelligence in Oncology Market, by Technology

• 7.1. Introduction
• 7.2. Computer Vision
  • 7.2.1. 3D Reconstruction
  • 7.2.2. Image Recognition
  • 7.2.3. Video Analysis
• 7.3. Machine Learning
  • 7.3.1. Deep Learning
  • 7.3.2. Supervised Learning
  • 7.3.3. Unsupervised Learning
• 7.4. Natural Language Processing
  • 7.4.1. Data Annotation
  • 7.4.2. Sentiment Analysis
  • 7.4.3. Text Mining
• 7.5. Robotic Process Automation
  • 7.5.1. Automated Workflows
  • 7.5.2. Clinical Documentation
  • 7.5.3. Process Mapping

8. Artificial Intelligence in Oncology Market, by Cancer Type

• 8.1. Introduction
• 8.2. Breast Cancer
• 8.3. Cervical Cancer
• 8.4. Colorectal Cancer
• 8.5. Esophageal Cancer
• 8.6. Liver Cancer
• 8.7. Lung Cancer
• 8.8. Skin Cancer
• 8.9. Stomach (Gastric) Cancer
• 8.10. Thyroid Cancer

9. Artificial Intelligence in Oncology Market, by Application

• 9.1. Introduction
• 9.2. Diagnostics
  • 9.2.1. Imaging Analytics
  • 9.2.2. Molecular Diagnostics
  • 9.2.3. Pathology
  • 9.2.4. Screening
• 9.3. Drug Discovery
  • 9.3.1. Clinical Trials Design
  • 9.3.2. Lead Discovery
  • 9.3.3. Target Identification
• 9.4. Outcome Prediction
  • 9.4.1. Complication Prediction
  • 9.4.2. Response Prediction
  • 9.4.3. Survival Rate Visualization
• 9.5. Personalized Medicine
  • 9.5.1. Biomarker Identification
  • 9.5.2. Genomic Data Analysis
  • 9.5.3. Therapeutic Optimization
• 9.6. Treatment Planning
  • 9.6.1. Chemotherapy Planning
  • 9.6.2. Radiation Therapy Planning
  • 9.6.3. Surgical Planning

10. Artificial Intelligence in Oncology Market, by End-Use

• 10.1. Introduction
• 10.2. Diagnostic Laboratories
  • 10.2.1. Genomic Testing Facilities
  • 10.2.2. Pathology Labs
• 10.3. Hospitals
  • 10.3.1. Private Hospitals
  • 10.3.2. Public Hospitals
• 10.4. Pharmaceutical Companies
  • 10.4.1. Generic Manufacturers
  • 10.4.2. Innovator Companies
• 10.5. Research Institutions
  • 10.5.1. Academic Institutions
  • 10.5.2. Biotech Firms

11. Americas Artificial Intelligence in Oncology Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Artificial Intelligence in Oncology Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Artificial Intelligence in Oncology Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Health Care Global Enterprises (HCG) collaborates with Accenture to revolutionize AI-driven cancer research and treatment
  • 14.3.2. Strategic partnership between BioAI and Arbele aims to revolutionize cancer treatment with AI-driven biomarker models
  • 14.3.3. Apollo's AI-powered Precision Oncology Centre in Bengaluru revolutionizes cancer diagnosis and care
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amazon Web Services, Inc.
• 2. Arterys, Inc.
• 3. Berg LLC
• 4. Bristol-Myers Squibb Company
• 5. Butterfly Network, Inc.
• 6. F. Hoffmann-La Roche Ltd.
• 7. Flatiron Health, Inc.
• 8. Freenome Holdings, Inc.
• 9. GE Healthcare
• 10. Google LLC by Alphabet Inc.
• 11. IBM Corporation
• 12. Intel Corporation
• 13. Koninklijke Philips N.V.
• 14. Medial EarlySign Ltd.
• 15. Microsoft Corporation
• 16. Nvidia Corporation
• 17. Oncora Medical, Inc.
• 18. Paige.AI Inc.
• 19. PathAI, Inc.
• 20. Siemens Healthineers AG
• 21. Tempus Labs, Inc.
• 22. Ultromics Limited
• 23. Viz.ai, Inc.
• 24. Zebra Medical Vision Ltd.